Vogenx Inc.(VOGX)

Biotechnology · Raleigh, NC

$16.39-0.76 (-4.43%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T21:29:27.294Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:29:27.294Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 227,913,489
Total debt: N/A
Cash: N/A
TTM free cash flow: N/A

FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

VOGX EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

VOGX Competitors' EV/FCF Ratio

VOGX

Vogenx Inc.

Current

Market Cap

$227.91M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BDSX

Biodesix, Inc.

vs VOGX

Market Cap

$227.60M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAUT

Nautilus Biotechnolgy, Inc.

vs VOGX

Market Cap

$225.24M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MGNX

MacroGenics, Inc.

vs VOGX

Market Cap

$231.37M

EV/FCF Ratio

N/A

TTM Avg

75.46x

3Y Avg

75.46x

5Y Avg

75.46x

GLSI

Greenwich LifeSciences, Inc.

vs VOGX

Market Cap

$231.77M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IFRX

InflaRx N.V.

vs VOGX

Market Cap

$232.72M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PROF

Profound Medical Corp.

vs VOGX

Market Cap

$220.93M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

UTMD

Utah Medical Products, Inc.

vs VOGX

Market Cap

$235.08M

EV/FCF Ratio

20.55x

TTM Avg

10.38x

3Y Avg

8.72x

5Y Avg

10.56x

AKBA

Akebia Therapeutics, Inc.

vs VOGX

Market Cap

$235.66M

EV/FCF Ratio

3.34x

TTM Avg

5.14x

3Y Avg

5.14x

5Y Avg

5.14x

SIGA

SIGA Technologies, Inc.

vs VOGX

Market Cap

$235.97M

EV/FCF Ratio

N/A

TTM Avg

3.75x

3Y Avg

11.33x

5Y Avg

12.44x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Vogenx Inc. (VOGX)	$227.91M	N/A	N/A	N/A	N/A
Biodesix, Inc. (BDSX)vs ›	$227.60M	N/A	N/A	N/A	N/A
Nautilus Biotechnolgy, Inc. (NAUT)vs ›	$225.24M	N/A	N/A	N/A	N/A
MacroGenics, Inc. (MGNX)vs ›	$231.37M	N/A	75.46x	75.46x	75.46x
Greenwich LifeSciences, Inc. (GLSI)vs ›	$231.77M	N/A	N/A	N/A	N/A
InflaRx N.V. (IFRX)vs ›	$232.72M	N/A	N/A	N/A	N/A
Profound Medical Corp. (PROF)vs ›	$220.93M	N/A	N/A	N/A	N/A
Utah Medical Products, Inc. (UTMD)vs ›	$235.08M	20.55x	10.38x	8.72x	10.56x
Akebia Therapeutics, Inc. (AKBA)vs ›	$235.66M	3.34x	5.14x	5.14x	5.14x
SIGA Technologies, Inc. (SIGA)vs ›	$235.97M	N/A	3.75x	11.33x	12.44x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

VOGX EV/FCF Ratio Metrics

VOGX Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics